IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 4, 2026

Meeting Format: Virtual

Time: 9:30 a.m. – 1:30 p.m.

Teams Meeting: https://teams.microsoft.com/meet/254652311313223?p=fzvaUV4setBCsk1WSo
Meeting ID: 254 652 311 313 223
Passcode: N7Dg2Xx7

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of August 5, 2026 Meeting Minutes
    b) August 2026 DUR Recommendation Letter to HHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Iowa Total Care
    b) Molina Healthcare
    c) Wellpoint Iowa
    d) Fee-for-Service
    e) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a **completed** conflict of interest disclosure. Must indicate if will be in-person or virtual testimony. Five (5) minute maximum limit.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CT October 28, 2026.**
    - **Send to pba_iadur@optum.com. Indicate if providing written or verbal comment.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Adherence to Disease Modifying Therapy for Multiple Sclerosis
        ii. Thiazide Diuretic Use in Members with Gout
    b) Proposal(s)
        i. Evaluation of Concurrent ACE Inhibitor/ARB, Diuretic, and NSAID Utilization and Associated Risk for Acute Kidney Injury
        ii. Recurrent Genitourinary Infections in Members Receiving an SGLT2 Inhibitor
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Prospective DUR
    a) Journavx (Suzetrigine) Age Edit
    b) Tramadol Quantity Limit
    c) Ezetimibe Statin Claims History Edit Review
8. Break (10 minutes)
9. Prior Authorization

a) Annual Review of Prior Authorization Criteria
b) Aldosterone Synthase Inhibitors
c) Apolipoprotein C-III Inhibitors
d) Oral Constipation Agents
e) Select Nephrology Agents

10. Miscellaneous
    a) DUR Digest Vol. 39, No. 1 – First Review
11. MedWatch
    FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
    FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
    FDA approves first drug to improve functional capacity and symptoms in children with rare inherited heart condition
    FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients
12. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay in your comments being considered until the next scheduled meeting. Reference complete public comment policy here.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
February 3, 2027
Meeting Format: Virtual